arrow
S

Stephen J. Kent

peter doherty institute for infection and immunity
H指数:76
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Randomised controlled phase I trial of a SARS ‐ CoV ‐2 monoclonal antibody

随机对照I期临床试验:一种<scp>SARS</scp>‐<scp>CoV</scp>‐2单克隆抗体

2026-11-040
OAAI
Atypical B cells and inflammatory profiles delineate immunity to influenza vaccination in First Nations and non-Indigenous people with chronic multimorbidity

非典型B细胞和炎症谱勾勒出慢性多病患的首创民族和非原住民对流感疫苗接种的免疫反应

2026-06-050
OAAI
High-dimensional multiomics reveals perturbations to IL-6/IL-6R axis and RUNX3 in CD4+ T cells during third-trimester pregnancy

高维多组学揭示孕晚期CD4+ T细胞中IL-6/IL-6R轴和RUNX3的扰动

2026-04-280
OAAI
Historic 1994 influenza vaccine cohorts define breadth of antibody and B cell responses toward future influenza A and B viruses

历史性的1994年流感疫苗队列定义了针对未来甲型和乙型流感病毒的抗体和B细胞反应的广度

2026-04-010
PRE
Elevated SARS-CoV-2 IgG4 in plasma and mucosa following repeated mRNA boosters impact antibody functions to Omicron and sarbecoviruses

重复mRNA加强针后血浆和黏膜中升高的SARS-CoV-2 IgG4对Omicron和sarbecoviruses的抗体功能产生影响

2025-12-200
OAAI
Low-level human memory T and B cells recognising avian influenza hemagglutinins are poorly responsive to existing seasonal influenza vaccines

识别禽流感血凝素的低水平人记忆性T和B细胞对现有的季节性流感疫苗反应不佳

2025-12-100
OAAI
A novel chimeric coronavirus spike vaccine combining SARS-CoV-2 RBD and scaffold domains from HKU-1 elicits potent neutralising antibody responses

一种新型嵌合冠状病毒刺突疫苗,结合了SARS-CoV-2 RBD和来自HKU-1的支架结构域,能够诱导强烈的中和抗体反应

2025-11-280
OAAI
Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination

实体瘤恶性患者中失调的炎症塑造了针对COVID-19疫苗接种的多功能抗体反应

2025-10-060
OA
Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial

流感特异性T细胞对疫苗接种的反应与基础血液恶性肿瘤无关:一项随机流感疫苗接种试验的分析

2025-07-010
PRE
Randomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccines
2025-01-090
OA